Biogen Idec Inc. is planning the first clinical trial that could lead to use of controversial multiple sclerosis treatment Tysabri, sold with Elan Corp, at earlier stages of the disease........... http://www.msrc.co.uk/index.cfm?fuseact ... ageid=1768